Funding for this research was provided by:
Merck
Article History
Accepted: 9 July 2021
First Online: 22 July 2021
Change Date: 3 August 2021
Change Type: Update
Change Details: Affiliation 4 was removed.
Declarations
:
: This research was supported by Merck & Co., Inc., Kenilworth, NJ, USA.
: Nan Qiao, Ralph Insinga, and Thomas Burke are employees of Merck & Co., Inc., Kenilworth, NJ, USA. Gilberto de Lima Lopes Junior is an employee of the University of Miami Clinical Oncology Sector, which received research grants from Merck & Co., Inc., Kenilworth, NJ, USA.
: Not applicable.
: Not applicable.
: Not applicable.
: Most model inputs and their sources are included in this paper. Patient-level data collected in KEYNOTE-024 and -042 are not available. The authors will assist with any reasonable replication attempts for 2 years following publication.
: Not available. The authors will assist with any reasonable replication attempts for 2 years following publication.
: Nan Qiao, Ralph Insinga, and Thomas Burke developed the study concept, and designed and planned the study. Nan Qiao built the cost-minimization model, conducted analyses, and drafted the manuscript. Ralph Insinga and Thomas Burke provided data inputs to the model. Gilberto de Lima Lopes Junior planned the study. All authors interpreted the results, critically reviewed and/or revised the manuscript, approved the content of the manuscript and its submission, and agreed to be accountable for all aspects of the manuscript.